Univariate Analysis for Platelet Recovery
| Variable . | Relative Risk . | 95% CI . | P . |
|---|---|---|---|
| Autologous PBSC | |||
| Baseline | |||
| Log10platelet (×109/L) | 3.46 | 2.13-5.60 | .0001 |
| Chemotherapy PBSC mobilization | 1.60 | 1.26-2.02 | .0001 |
| Log10 CD34 (×106/kg) | 1.02 | 1.01-1.03 | .0001 |
| Prior stem cell transplant | 1.89 | 1.16-3.09 | .01 |
| Breast cancer* | Reference | ||
| Leukemia* | 0.32 | 0.18-0.56 | .0001 |
| Non-Hodgkin's lymphoma* | 0.63 | 0.46-0.85 | .003 |
| Hodgkin's disease* | 0.62 | 0.39-0.98 | .04 |
| Other solid tumors* | 0.59 | 0.36-0.97 | .04 |
| XRT-containing preparative regimen | 0.62 | 0.46-0.83 | .001 |
| Log10 mononuclear cell (×108/kg) | 0.62 | 0.44-0.89 | .009 |
| Time dependent | |||
| Neutrophil recovery | 7.59 | 5.25-10.95 | .0001 |
| Fever >39°C | 0.67 | 0.52-0.86 | .002 |
| Veno-occlusive disease | 0.30 | 0.09-0.93 | .04 |
| Allogeneic BMT | |||
| Baseline | |||
| HLA-identical sibling donor | 1.80 | 1.35-2.40 | .0001 |
| Log10 total nucleated cells (×108/kg) | 1.53 | 1.01-2.32 | .05 |
| Chronic myeloid leukemia* | Reference | — | |
| Acute myeloid leukemia* | 0.70 | 0.48-1.02 | .06 |
| Marrow graft manipulation | 0.64 | 0.45-0.90 | .01 |
| T-cell–depleted marrow | 0.54 | 0.33-0.91 | .02 |
| XRT-containing preparative regimen | 0.72 | 0.53-0.97 | .03 |
| Time dependent | |||
| Neutrophil recovery | 3.16 | 2.13-4.69 | .0001 |
| Posttransplant growth factor* | 0.63 | 0.47-0.84 | .002 |
| Fever >39°C | 0.55 | 0.36-0.82 | .003 |
| Veno-occlusive disease | 0.45 | 0.26-0.77 | .004 |
| GVHD (grade II-V) | 0.60 | 0.40-0.89 | .01 |
| Fever 38-39°C | 0.66 | 0.47-0.92 | .01 |
| Variable . | Relative Risk . | 95% CI . | P . |
|---|---|---|---|
| Autologous PBSC | |||
| Baseline | |||
| Log10platelet (×109/L) | 3.46 | 2.13-5.60 | .0001 |
| Chemotherapy PBSC mobilization | 1.60 | 1.26-2.02 | .0001 |
| Log10 CD34 (×106/kg) | 1.02 | 1.01-1.03 | .0001 |
| Prior stem cell transplant | 1.89 | 1.16-3.09 | .01 |
| Breast cancer* | Reference | ||
| Leukemia* | 0.32 | 0.18-0.56 | .0001 |
| Non-Hodgkin's lymphoma* | 0.63 | 0.46-0.85 | .003 |
| Hodgkin's disease* | 0.62 | 0.39-0.98 | .04 |
| Other solid tumors* | 0.59 | 0.36-0.97 | .04 |
| XRT-containing preparative regimen | 0.62 | 0.46-0.83 | .001 |
| Log10 mononuclear cell (×108/kg) | 0.62 | 0.44-0.89 | .009 |
| Time dependent | |||
| Neutrophil recovery | 7.59 | 5.25-10.95 | .0001 |
| Fever >39°C | 0.67 | 0.52-0.86 | .002 |
| Veno-occlusive disease | 0.30 | 0.09-0.93 | .04 |
| Allogeneic BMT | |||
| Baseline | |||
| HLA-identical sibling donor | 1.80 | 1.35-2.40 | .0001 |
| Log10 total nucleated cells (×108/kg) | 1.53 | 1.01-2.32 | .05 |
| Chronic myeloid leukemia* | Reference | — | |
| Acute myeloid leukemia* | 0.70 | 0.48-1.02 | .06 |
| Marrow graft manipulation | 0.64 | 0.45-0.90 | .01 |
| T-cell–depleted marrow | 0.54 | 0.33-0.91 | .02 |
| XRT-containing preparative regimen | 0.72 | 0.53-0.97 | .03 |
| Time dependent | |||
| Neutrophil recovery | 3.16 | 2.13-4.69 | .0001 |
| Posttransplant growth factor* | 0.63 | 0.47-0.84 | .002 |
| Fever >39°C | 0.55 | 0.36-0.82 | .003 |
| Veno-occlusive disease | 0.45 | 0.26-0.77 | .004 |
| GVHD (grade II-V) | 0.60 | 0.40-0.89 | .01 |
| Fever 38-39°C | 0.66 | 0.47-0.92 | .01 |
*Median (95% CI) day of platelet recovery: breast cancer, 12 (11, 12); leukemia [ALL, 24.5 (20, NA); AML, 19.0 (15, NA); CML, 28.0 (10, NA)]; non-Hodgkin's lymphoma, 13 (12, 14); Hodgkin's disease, 13 (12, 22); other solid tumors, 15 (13, 17); chronic myeloid leukemia, 25 (24, 28); acute myeloid leukemia, 30 (25, 36); posttransplant growth factor, 30 (27, 35); no posttransplant growth factor, 24 (23, 25); 95% CI-95% confidence interval; reference, used as the reference disease, as this is the diagnosis with the largest number of cases; NA, not available, because of the large number of patients.